Introduction

In a significant outcome for branded pharmaceutical patent protection, a series of consent judgments entered between June and July 2024 resolved AstraZeneca’s patent infringement action against generic manufacturers seeking to market acalabrutinib capsules — the active ingredient in CALQUENCE®, AstraZeneca’s commercially vital BTK inhibitor approved for treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Filed on February 2, 2022, in the District of Delaware under Case No. 1:22-cv-00154, the litigation brought by Acerta Pharma B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, and Merck Sharp & Dohme B.V. targeted Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc., and other generic filers who submitted Abbreviated New Drug Applications (ANDAs) for 100 mg acalabrutinib oral capsules. The case closed on July 15, 2024, with all defendants exiting through negotiated consent judgments — a resolution pattern carrying meaningful implications for Hatch-Waxman patent litigation strategy across the pharmaceutical sector.

Case Overview

The Parties

The Patents at Issue

This landmark case involved six U.S. patents covering the foundational compound chemistry, structural/synthesis claims, chemical composition, formulation-related claims, and downstream innovations related to acalabrutinib. This multi-patent stack is characteristic of sophisticated pharmaceutical lifecycle management, creating layered exclusivity that generic entrants must navigate entirely.

• • US7459554B2 — foundational compound chemistry
• • US9758524B2 — structural/synthesis claims
• • US9796721B2 — related chemical composition claims
• • US10167291B2 — method or formulation-related claims
• • US10239883B2 — downstream claims covering acalabrutinib innovations
• • US10272083B2 — additional composition or use claims

Litigation Timeline & Procedural History

The complaint was filed on February 2, 2022, initiating what would become a 894-day litigation cycle — typical for complex Hatch-Waxman multi-patent, multi-defendant cases in Delaware.

Delaware venue selection was strategically significant. The District of Delaware remains the preeminent forum for pharmaceutical patent litigation, with judges experienced in ANDA disputes, predictable scheduling orders, and institutional familiarity with Hatch-Waxman mechanics. The case was presided over by Judge Gregory B. Williams, who signed all three consent judgment orders.

The docket reflects consolidated ANDA litigation against multiple generic filers — a common plaintiff strategy that maximizes efficiency and settlement leverage. Over approximately two years of litigation, the case progressed through pleadings and discovery phases before resolving through a structured series of negotiated exits:

• June 5, 2024 — Consent Judgment entered as to Alembic Pharmaceuticals Limited
• June 12, 2024 — Consent Judgment entered as to Cipla Limited and Cipla USA Inc.
• July 15, 2024 — Consent Judgment entered as to MSN Laboratories; civil case terminated

A Report to the Commissioner of Patents and Trademarks was filed on July 15, 2024, fulfilling the statutory notification requirement under 35 U.S.C. § 290.

The Verdict & Legal Analysis

Outcome

The case resolved entirely through consent judgments — negotiated, court-ordered resolutions — rather than contested trial verdicts. No specific damages amounts were publicly disclosed in the available record. Each consent judgment reflects a bilateral agreement between the parties, approved and entered by Judge Williams, terminating defendants’ participation in the litigation. The terms of any licensing arrangements, entry dates, or market access provisions agreed upon by the parties were not disclosed in the public docket.

Verdict Cause Analysis

This was a classic Hatch-Waxman ANDA patent infringement action under 35 U.S.C. § 271(e)(2), triggered by defendants’ filing of ANDAs with Paragraph IV certifications asserting that AstraZeneca’s listed patents were invalid, unenforceable, or would not be infringed by the generic product. The consent judgment resolutions — without any public findings of invalidity or non-infringement — suggest that defendants did not successfully overcome the six-patent portfolio through litigation.

In Hatch-Waxman litigation, consent judgments frequently encode negotiated authorized generic arrangements or market entry date agreements, where generic manufacturers accept delayed market entry in exchange for litigation resolution. The sequential exit pattern here — Alembic first, then Cipla, then MSN — is consistent with individual settlement negotiations proceeding in parallel with litigation, each resolved on separate terms.

The breadth of the patent portfolio asserted — six patents spanning foundational chemistry through downstream claims — presented a formidable challenge for generic defendants. Invalidating even one patent would be insufficient if others remained valid and infringed; defendants faced the burden of addressing the entire patent stack.

Legal Significance

This case reinforces several important principles in pharmaceutical patent practice:

• Multi-patent portfolio strategy works. By asserting six patents across different claim types (compound, composition, method), AstraZeneca created a litigation environment that significantly raises the cost and risk calculus for generic challengers. No single invalidity argument could extinguish all exclusivity.
• Delaware consent judgment patterns. The sequential entry of consent judgments against multiple defendants reflects sophisticated plaintiff-side litigation management — resolving defendants individually as settlement terms mature while maintaining litigation pressure on remaining parties.
• Report to USPTO. The July 15, 2024 report to the Commissioner of Patents and Trademarks pursuant to 35 U.S.C. § 290 documents the litigation’s resolution in the official patent record — relevant for future prosecution history or licensing due diligence.

Industry & Competitive Implications

CALQUENCE® competes directly in the BTK inhibitor market against Pharmacyclics/AbbVie’s IMBRUVICA® (ibrutinib). With acalabrutinib demonstrating a differentiated safety profile and growing CLL market share, AstraZeneca’s motivation to protect exclusivity through vigorous ANDA litigation was commercially compelling.

The consent judgment outcomes effectively preserve AstraZeneca’s market position against the three generic filers involved. However, the negotiated nature of these resolutions means future ANDA filers — or parties not bound by these judgments — retain the ability to challenge the same patent portfolio independently.

For the generic industry, the case underscores the resource intensity of multi-defendant Hatch-Waxman litigation against a well-resourced innovator with a diversified patent portfolio. The sequential resolution also demonstrates that even coordinated generic entry strategies can be fragmented through individual settlement negotiations.

Broader licensing and settlement trends in pharmaceutical patent litigation increasingly favor negotiated entry date agreements over full trial adjudication — a pattern this case exemplifies.